Key Highlights

  • NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) rose 10.7% to about USD 3.62 in early trading on Monday, October 26, 2026, after a company release at 9:19 a.m. ET on a planned brain cancer trial.
  • The release describes a planned trial of about 500 patients at about 30 hospitals in three countries, and states that these are planned figures, not completed enrolment.
  • The investigational therapy NEO100 is delivered intranasally to bypass the blood-brain barrier, and the trial would evaluate patients with IDH mutations, a genetic alteration found in some gliomas.
  • The release lists the ability to continue as a going concern among its risk factors, and it states that the publisher is compensated by the company.

A Trial Plan Released Before the Open

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage company developing treatments for brain cancer, rose 10.7% to about USD 3.62 in early trading on Monday, October 26, 2026. The move followed a company release issued at 9:19 a.m. ET that day, so the shares were moving as the regular session opened. The release outlines a planned trial of about 500 patients at about 30 hospitals in three countries for NEO100, an investigational therapy delivered through the nose. It does not specify the trial phase, financing or cash position. The release also refers to a televised interview appearance connected to the company. Earlier company updates included a board appointment announcement on Wednesday, October 14, 2026, tied to a new path for drug development in Abu Dhabi.

Why Intranasal Delivery and Scale Matter

Many brain tumour drugs struggle because the blood-brain barrier, a membrane that limits which substances reach the brain, blocks them. NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) says NEO100 is delivered intranasally to bypass that barrier. The release cites a December 2025 clinical update that reported significant radiographic remission in 6 of 25 patients across clinical and compassionate-use experience, together with a 24% remission figure. The company itself describes these as preliminary results from a small, nonrandomised group that do not establish effectiveness. A 500-patient programme across three countries would be a far larger test than that group, and plans of that kind often move small biotechnology shares because they signal a path to a registrational dataset.

Risks and What to Watch

The principal risk for NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) is funding. The release lists the ability to continue as a going concern among its risk factors, and a trial of this scale would require substantial capital, which in small companies is often raised through share offerings that dilute holders. Short interest was reported to have risen about 45% to 758,000 shares in a recent update, which can magnify swings. The planned figures may change, the phase and regulatory path are unstated, and early remission data are not proof of efficacy. Investors should watch for a financing announcement, regulatory clearance for the trial, the Fed decision on Wednesday, October 28, 2026, and any further company updates.

Where Things Stand

The answer is that NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) rose 10.7% to about USD 3.62 in early trading on Monday, October 26, 2026 because of a plan, not a result: a proposed 500-patient trial with no stated phase, funding or start date. The next catalysts are any financing, regulatory filing or trial start update, and the Fed decision on Wednesday, October 28, 2026. Clinical-stage shares can reverse quickly, preliminary data are not guarantees, and this is not investment advice.